SI3463328T1 - Seladelpar za zdravljenje primarnega biliarnega holangitisa - Google Patents

Seladelpar za zdravljenje primarnega biliarnega holangitisa

Info

Publication number
SI3463328T1
SI3463328T1 SI201731175T SI201731175T SI3463328T1 SI 3463328 T1 SI3463328 T1 SI 3463328T1 SI 201731175 T SI201731175 T SI 201731175T SI 201731175 T SI201731175 T SI 201731175T SI 3463328 T1 SI3463328 T1 SI 3463328T1
Authority
SI
Slovenia
Prior art keywords
seladelpar
treatment
primary biliary
biliary cholangitis
cholangitis
Prior art date
Application number
SI201731175T
Other languages
English (en)
Slovenian (sl)
Inventor
Pol Boudes
Charles A. Mcwherter
Original Assignee
Cymabay Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics, Inc. filed Critical Cymabay Therapeutics, Inc.
Publication of SI3463328T1 publication Critical patent/SI3463328T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201731175T 2016-05-31 2017-04-26 Seladelpar za zdravljenje primarnega biliarnega holangitisa SI3463328T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662343688P 2016-05-31 2016-05-31
EP17722943.2A EP3463328B1 (en) 2016-05-31 2017-04-26 Seladelpar for the treatment of primary biliary cholangitis
PCT/US2017/029620 WO2017209865A1 (en) 2016-05-31 2017-04-26 Treatment of intrahepatic cholestatic diseases

Publications (1)

Publication Number Publication Date
SI3463328T1 true SI3463328T1 (sl) 2022-08-31

Family

ID=58699276

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731175T SI3463328T1 (sl) 2016-05-31 2017-04-26 Seladelpar za zdravljenje primarnega biliarnega holangitisa

Country Status (27)

Country Link
US (5) US10272058B2 (enExample)
EP (1) EP3463328B1 (enExample)
JP (1) JP7079735B2 (enExample)
KR (1) KR102408288B1 (enExample)
CN (2) CN121466055A (enExample)
AU (1) AU2017274293B2 (enExample)
BR (1) BR112018074147A2 (enExample)
CA (1) CA3024155C (enExample)
CY (1) CY1125465T1 (enExample)
DK (1) DK3463328T3 (enExample)
ES (1) ES2921230T3 (enExample)
HR (1) HRP20220903T1 (enExample)
HU (1) HUE059838T2 (enExample)
IL (1) IL263372B2 (enExample)
LT (1) LT3463328T (enExample)
MX (1) MX390417B (enExample)
NZ (1) NZ748721A (enExample)
PL (1) PL3463328T3 (enExample)
PT (1) PT3463328T (enExample)
RS (1) RS63345B1 (enExample)
RU (1) RU2765460C2 (enExample)
SG (1) SG11201810123SA (enExample)
SI (1) SI3463328T1 (enExample)
SM (1) SMT202200471T1 (enExample)
UA (1) UA122719C2 (enExample)
WO (1) WO2017209865A1 (enExample)
ZA (1) ZA201808360B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
RS57970B1 (sr) 2014-03-20 2019-01-31 Cymabay Therapeutics Inc Tretman intrahepatičkih holestatskih oboljenja
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
EP3880185A1 (en) * 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Combination treatment of nafld and nash
US20220241228A1 (en) 2021-02-01 2022-08-04 Cymabay Therapeutics, Inc. Treatment of cholangiopathies
WO2024180642A1 (ja) 2023-02-28 2024-09-06 株式会社日立ハイテク プラズマ処理装置およびプラズマ処理装置の試料台の製造方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
WO1996027606A1 (en) 1995-03-06 1996-09-12 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
NZ331217A (en) 1996-02-14 2000-02-28 Novartis Ag Sugar-modified gapped oligonucleotides for eliciting RNase H activity for strand cleavage in an opposing strand
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
WO2005042478A2 (en) 2003-09-19 2005-05-12 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
KR101494067B1 (ko) 2004-03-05 2015-02-16 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
CA2740874C (en) 2008-10-17 2018-02-27 Metabolex, Inc. Use of ppar.gamma.agonists to reduce small dense ldl particles
SG175390A1 (en) * 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
NZ602125A (en) 2010-03-30 2014-01-31 Novartis Ag Uses of dgat1 inhibitors
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
HK1224186A1 (zh) 2013-11-20 2017-08-18 Cymabay Therapeutics, Inc. 纯阖家族型高胆固醇血症的治疗
RS57970B1 (sr) 2014-03-20 2019-01-31 Cymabay Therapeutics Inc Tretman intrahepatičkih holestatskih oboljenja
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
KR102374499B1 (ko) 2014-04-11 2022-03-14 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash 의 치료
EP3160458A1 (en) 2014-06-26 2017-05-03 Cymabay Therapeutics, Inc. Treatment of severe hypertriglyceridemia
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
DK3973959T3 (da) 2017-09-26 2025-01-20 Cymabay Therapeutics Inc Behandling af kolestatisk kløe med seladelpar
EP3880187A1 (en) 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Treatment of obesity and its complications
EP3880185A1 (en) 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Combination treatment of nafld and nash

Also Published As

Publication number Publication date
PT3463328T (pt) 2022-07-07
RU2018146504A (ru) 2020-07-09
US20210000774A1 (en) 2021-01-07
JP2019518022A (ja) 2019-06-27
HRP20220903T1 (hr) 2022-10-14
CY1125465T1 (el) 2025-05-09
US20200061006A1 (en) 2020-02-27
CN121466055A (zh) 2026-02-06
SG11201810123SA (en) 2018-12-28
JP7079735B2 (ja) 2022-06-02
US20190255004A1 (en) 2019-08-22
CA3024155C (en) 2023-10-10
KR102408288B1 (ko) 2022-06-10
PL3463328T3 (pl) 2022-10-03
US20210220305A1 (en) 2021-07-22
WO2017209865A1 (en) 2017-12-07
MX2018014915A (es) 2019-04-24
AU2017274293A1 (en) 2018-12-13
EP3463328A1 (en) 2019-04-10
RU2765460C2 (ru) 2022-01-31
RU2018146504A3 (enExample) 2020-07-27
BR112018074147A2 (pt) 2019-03-06
HUE059838T2 (hu) 2023-01-28
AU2017274293B2 (en) 2022-03-31
US20170340589A1 (en) 2017-11-30
SMT202200471T1 (it) 2023-01-13
LT3463328T (lt) 2022-08-10
ES2921230T3 (es) 2022-08-22
CN109195594A (zh) 2019-01-11
US10272058B2 (en) 2019-04-30
MX390417B (es) 2025-03-20
UA122719C2 (uk) 2020-12-28
IL263372B2 (en) 2023-06-01
RS63345B1 (sr) 2022-07-29
DK3463328T3 (da) 2022-07-04
US11000494B2 (en) 2021-05-11
ZA201808360B (en) 2020-02-26
US10813895B2 (en) 2020-10-27
US11596614B2 (en) 2023-03-07
EP3463328B1 (en) 2022-06-15
US10478411B2 (en) 2019-11-19
CA3024155A1 (en) 2017-12-07
KR20190015363A (ko) 2019-02-13
NZ748721A (en) 2022-04-29
IL263372A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
CY2025027I2 (el) Ελαφιμπρανορη για χρηση στην αντιμετωπιση πρωτοπαθους χολικης χολαγγειτιδας
DK3728271T3 (da) Makrocykliske forbindelser til behandling af sygdomme
DK3515937T3 (da) Behandling af refraktorisk migræne
SI3143025T1 (sl) Spojine za zdravljenje spinalne mišične atrofije
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
HUE055263T2 (hu) 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
DK3506904T3 (da) Behandling af demens
ZA201903649B (en) Treatment for primary biliary cholangitis
SI3463328T1 (sl) Seladelpar za zdravljenje primarnega biliarnega holangitisa
SI3573620T1 (sl) Sestavki za zdravljenje hipertenzije
DK3430143T3 (da) Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme
DK3331610T3 (da) Midler til anvendelse til behandling af gliom
DK3286317T3 (da) Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi
CY2024037I1 (el) Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων
DK3506901T3 (da) Anvendelse af kynurensyre til behandling af muskelatrofi
EP3493821A4 (en) METHOD OF TREATING THE RESPIRATORY TRACT
GB201603546D0 (en) Treatment of urine
HUE062859T2 (hu) Szennyvíz kezelése
PL3582796T3 (pl) Kompozycja do leczenia kaszlu
DK3500572T3 (da) Cytisinderivater til behandling af afhængighed
DK3250218T3 (da) Naktidpeptid til behandling af fedme
DK3200783T3 (da) Behandling af erytromelalgi